Roy S. Herbst, MD, PhD, is the ensign professor of medicine and pharmacology at Yale School of Medicine and serves as deputy director for Yale Cancer Center, chief of medical oncology and hematology, and program director of the Master of Health Science Clinical Investigation for Yale School of Medicine. He is the principal investigator of several significant research initiatives, including the Yale SPORE in Lung Cancer and the Yale-AstraZeneca Alliance and his research has led the development of numerous targeted therapies for lung cancer such as gefitinib, erlotinib, osimertinib, cetuximab, bevacizumab, axitinib, and multiple anti-PD1/PDL1 therapies. Additionally, his research has helped bring targeted therapy to early-stage disease and led to defining biomarkers as standard for the use of targeted therapies. He has authored or co-authored over 500 publications and received awards such as the Clinical Research Forum’s 2015 Herbert Pardes Clinical Research Excellence Award, the 2022 Giants of Cancer Care® award, and the 2024 Ezra Greenspan Award. He is a member of the National Cancer Policy Forum, the NCI Thoracic Malignancies Steering Committee, the Association of American Physicians, and Chair of the American Association for Cancer Research Science Policy and Government Affairs Committee.
